Education
About Us
Working with TipRanks
Follow Us
Nuvectis Pharma (NVCT)
NASDAQ:NVCT
NVCT Stock Chart & Stats
$8.46
-$0.26(-4.17%)
At close: 4:00 PM EST
$8.46
-$0.26(-4.17%)
Day’s Range― - ―
52-Week Range$5.55 - $11.52
Previous CloseN/A
Volume31.37K
Average Volume (3M)89.48K
Market Cap
$216.70M
Enterprise Value$181.26M
Total Cash (Recent Filing)$35.44M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.67
Next Earnings
Mar 10, 2026EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.44
Shares Outstanding25,614,897
10 Day Avg. Volume112,705
30 Day Avg. Volume89,483
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)9.53
Price to Sales (P/S)0.00
P/FCF Ratio-7.56
Enterprise Value/Market Cap0.84
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-7.02
Forecast
1Y Price Target
$15.67Price Target Upside85.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.06
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Combination Therapy FeasibilityA favorable safety profile and a drug-drug interaction study supporting coadministration with osimertinib and lorlatinib increase the feasibility of combining NXP900 with standard targeted backbones.
Market Opportunity And Trial DesignBroad combo-enrollment criteria that do not require specific genetic alterations expand the eligible patient pool in the fragmented non-small-cell lung cancer landscape with limited targeted options.
Mechanism Of ActionNXP900's ability to lock YES1/YAP1 in an inactive form targets Hippo pathway dysregulation and could resensitize EGFR- and ALK-resistant tumors to existing therapies.
Bears Say
Precedent Risk With Src InhibitorsPrevious combination programs using Src inhibitors failed to demonstrate benefit due to inadequate Src inhibition, indicating class-specific execution risk for NXP900 development.
Nuvectis Pharma News
NVCT FAQ
What was Nuvectis Pharma’s price range in the past 12 months?
Nuvectis Pharma lowest stock price was $5.55 and its highest was $11.52 in the past 12 months.
What is Nuvectis Pharma’s market cap?
Nuvectis Pharma’s market cap is $216.70M.
When is Nuvectis Pharma’s upcoming earnings report date?
Nuvectis Pharma’s upcoming earnings report date is Mar 10, 2026 which is in 32 days.
How were Nuvectis Pharma’s earnings last quarter?
Nuvectis Pharma released its earnings results on Nov 04, 2025. The company reported -$0.44 earnings per share for the quarter, missing the consensus estimate of -$0.25 by -$0.19.
Is Nuvectis Pharma overvalued?
According to Wall Street analysts Nuvectis Pharma’s price is currently Undervalued.
Does Nuvectis Pharma pay dividends?
Nuvectis Pharma does not currently pay dividends.
What is Nuvectis Pharma’s EPS estimate?
Nuvectis Pharma’s EPS estimate is -0.31.
How many shares outstanding does Nuvectis Pharma have?
Nuvectis Pharma has 25,614,897 shares outstanding.
What happened to Nuvectis Pharma’s price movement after its last earnings report?
Nuvectis Pharma reported an EPS of -$0.44 in its last earnings report, missing expectations of -$0.25. Following the earnings report the stock price went down -7.547%.
Which hedge fund is a major shareholder of Nuvectis Pharma?
Currently, no hedge funds are holding shares in NVCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nuvectis Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.67 (85.22% Upside)
$15.67 (85.22% Upside)
Blogger Sentiment
Neutral
NVCT Sentiment 50%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $168.1K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
82.74%
12-Months-Change
Fundamentals
Return on Equity
-158.88%
Trailing 12-Months
Asset Growth
105.62%
Trailing 12-Months
Company Description
Nuvectis Pharma
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
NVCT Stock 12 Month Forecast
Average Price Target
$15.67
▲(85.22% Upside)
Technical Analysis
Nkarta
―
Orchestra BioMed Holdings
―
Greenwich LifeSciences
―
Molecular Partners
―
Pyxis Oncology
―
Ownership Overview
43.51% Insiders
3.63% Mutual Funds
1.75% Other Institutional Investors
46.12% Public Companies and
Individual Investors